IDEXX Laboratories Stock - Analyst views and valuation debate
Published on 06/17/2026 at 19:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:20 UTC. Details in the imprint.
IDEXX Laboratories (US45168D1046) is a long-established name in veterinary diagnostics and software on the Nasdaq. With no fresh company filings or market-moving headlines today, the focus shifts to how the stock’s valuation and growth profile look in the current mid-2026 setting.
All news and background on IDEXX Laboratories stock
Price data, past earnings and company releases give additional context for how IDEXX Laboratories is currently valued in the veterinary diagnostics sector.
How the valuation looks now
Recent data from specialist platforms put IDEXX Laboratories stock at about $573 per share, implying a market capitalization slightly above $41 billion in mid-2026. That level is well below the 52-week high near $770 but comfortably above the 52-week low around $507.
One analysis describes the shares trading at roughly 42 times earnings, calling it a “slowing growth story” after a period of strong multiple expansion. The same review notes the stock is down about 15% year-to-date and roughly 18% over the last 120 days, underperforming many broader US equity benchmarks.
Analyst and investor perspectives
Longer-term investors have still seen robust gains. A Benzinga performance review calculates that IDEXX Laboratories has materially outpaced the market over the past decade, with a hypothetical $100 investment at the time of its study growing several-fold by mid-2026. The article uses a reference price of $573 for IDXX at the time of writing.
Options-market data compiled by MarketBeat point to continued active trading interest, with listed contracts across a wide range of expiries and strike prices. That breadth of liquidity suggests the stock remains a regular tool for both directional and hedging strategies among institutional and active retail investors.
The business behind the stock
IDEXX Laboratories generates most of its revenue from diagnostic instruments, consumables and reference laboratory services for companion-animal veterinary practices. The company also sells practice management software and water testing products, positioning itself as a full-service diagnostics and workflow partner for clinics and laboratories worldwide.
Where the stock trades today
The shares of IDEXX Laboratories (US45168D1046) trade on the Nasdaq at $573.00 as of 06/17/2026, 15:55 ET.
Key facts on IDEXX Laboratories stock
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- WKN: 888210
- Ticker: IDXX
- Venue: Nasdaq
- Price (as of 06/17/2026, 15:55 ET): 573.00 USD
- Market cap: 41,540,000,000 USD (as of 05/12/2026)
- Sector / Industry: Health Care - Veterinary diagnostics and equipment
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
